aricogan 10 mg tabletes
g.l. pharma gmbh, austria - aripiprazols - tablete - 10 mg
amoxicillin/clavulanic acid vale 500 mg/125 mg apvalkotās tabletes
vale pharmaceuticals limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 500 mg/125 mg
amoxicillin/clavulanic acid vale 875 mg/125 mg apvalkotās tabletes
vale pharmaceuticals limited, ireland - amoxicillinum, skābes clavulanicum - apvalkotā tablete - 875 mg/125 mg
raploc 300 mg pulveris infūziju šķīduma pagatavošanai
amomed pharma gmbh, austria - landiolola hidrohlorīds - pulveris infūziju šķīduma pagatavošanai - 300 mg
raploc 20 mg/2 ml koncentrāts injekciju šķīduma pagatavošanai
amomed pharma gmbh, austria - landiolola hidrohlorīds - koncentrāts injekciju šķīduma pagatavošanai - 20 mg/2 ml
asacol 800 mg ilgstošās darbības tabletes
tillotts pharma ab, sweden - mesalazīns - modificētās darbības tablete - 800 mg
asacol 400 mg ilgstošās darbības tabletes
tillotts pharma ab, sweden - mesalazīns - modificētās darbības tablete - 400 mg
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfoma, mantle-cell - antineoplastiski līdzekļi - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
evrysdi
roche registration gmbh - risdiplam - muskuļu atrofija, mugurkaula - other drugs for disorders of the musculo-skeletal system - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmoloģiskie līdzekļi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).